Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Aristoteles Giagounidis, Pierre Fenaux, Ghulam J. Mufti, Petra Muus, Uwe Platzbecker, Guillermo Sanz, Larry Cripe, Marie Lilienfeld-Toal, Richard A. Wells

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q (del(5q)) cytogenetic abnormality. Although some patients with del(5q) have a relatively good prognosis, all del(5q) patients will become transfusion-dependent at some point during the course of their disease. The results of two clinical trials in more than 160 patients with MDS have demonstrated clear therapeutic benefits of lenalidomide, with >60% of patients achieving independence from transfusion during therapy, irrespective of age, prior therapy, sex, or disease-risk assessment. The recommendations presented in this review will aid the safe administration of lenalidomide for the treatment of patients with low-risk or intermediate-1-risk MDS and a del(5q) cytogenetic abnormality, and they will help physicians avoid unnecessary dose reduction or interruption, thus assuring the best efficacy for patients.

Original languageEnglish
Pages (from-to)345-352
Number of pages8
JournalAnnals of Hematology
Volume87
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Myelodysplastic Syndromes
Chromosome Aberrations
United States Food and Drug Administration
Therapeutics
lenalidomide
Clinical Trials
Physicians

Keywords

  • Lenalidomide
  • MDS
  • Myelodysplastic syndromes
  • Treatment guidelines

ASJC Scopus subject areas

  • Hematology

Cite this

Giagounidis, A., Fenaux, P., Mufti, G. J., Muus, P., Platzbecker, U., Sanz, G., ... Wells, R. A. (2008). Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Annals of Hematology, 87(5), 345-352. https://doi.org/10.1007/s00277-008-0449-0

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. / Giagounidis, Aristoteles; Fenaux, Pierre; Mufti, Ghulam J.; Muus, Petra; Platzbecker, Uwe; Sanz, Guillermo; Cripe, Larry; Lilienfeld-Toal, Marie; Wells, Richard A.

In: Annals of Hematology, Vol. 87, No. 5, 05.2008, p. 345-352.

Research output: Contribution to journalArticle

Giagounidis, A, Fenaux, P, Mufti, GJ, Muus, P, Platzbecker, U, Sanz, G, Cripe, L, Lilienfeld-Toal, M & Wells, RA 2008, 'Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes', Annals of Hematology, vol. 87, no. 5, pp. 345-352. https://doi.org/10.1007/s00277-008-0449-0
Giagounidis, Aristoteles ; Fenaux, Pierre ; Mufti, Ghulam J. ; Muus, Petra ; Platzbecker, Uwe ; Sanz, Guillermo ; Cripe, Larry ; Lilienfeld-Toal, Marie ; Wells, Richard A. / Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. In: Annals of Hematology. 2008 ; Vol. 87, No. 5. pp. 345-352.
@article{180c5dc931f14c7f862b57e92db7d1c6,
title = "Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes",
abstract = "Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q (del(5q)) cytogenetic abnormality. Although some patients with del(5q) have a relatively good prognosis, all del(5q) patients will become transfusion-dependent at some point during the course of their disease. The results of two clinical trials in more than 160 patients with MDS have demonstrated clear therapeutic benefits of lenalidomide, with >60{\%} of patients achieving independence from transfusion during therapy, irrespective of age, prior therapy, sex, or disease-risk assessment. The recommendations presented in this review will aid the safe administration of lenalidomide for the treatment of patients with low-risk or intermediate-1-risk MDS and a del(5q) cytogenetic abnormality, and they will help physicians avoid unnecessary dose reduction or interruption, thus assuring the best efficacy for patients.",
keywords = "Lenalidomide, MDS, Myelodysplastic syndromes, Treatment guidelines",
author = "Aristoteles Giagounidis and Pierre Fenaux and Mufti, {Ghulam J.} and Petra Muus and Uwe Platzbecker and Guillermo Sanz and Larry Cripe and Marie Lilienfeld-Toal and Wells, {Richard A.}",
year = "2008",
month = "5",
doi = "10.1007/s00277-008-0449-0",
language = "English",
volume = "87",
pages = "345--352",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

AU - Giagounidis, Aristoteles

AU - Fenaux, Pierre

AU - Mufti, Ghulam J.

AU - Muus, Petra

AU - Platzbecker, Uwe

AU - Sanz, Guillermo

AU - Cripe, Larry

AU - Lilienfeld-Toal, Marie

AU - Wells, Richard A.

PY - 2008/5

Y1 - 2008/5

N2 - Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q (del(5q)) cytogenetic abnormality. Although some patients with del(5q) have a relatively good prognosis, all del(5q) patients will become transfusion-dependent at some point during the course of their disease. The results of two clinical trials in more than 160 patients with MDS have demonstrated clear therapeutic benefits of lenalidomide, with >60% of patients achieving independence from transfusion during therapy, irrespective of age, prior therapy, sex, or disease-risk assessment. The recommendations presented in this review will aid the safe administration of lenalidomide for the treatment of patients with low-risk or intermediate-1-risk MDS and a del(5q) cytogenetic abnormality, and they will help physicians avoid unnecessary dose reduction or interruption, thus assuring the best efficacy for patients.

AB - Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q (del(5q)) cytogenetic abnormality. Although some patients with del(5q) have a relatively good prognosis, all del(5q) patients will become transfusion-dependent at some point during the course of their disease. The results of two clinical trials in more than 160 patients with MDS have demonstrated clear therapeutic benefits of lenalidomide, with >60% of patients achieving independence from transfusion during therapy, irrespective of age, prior therapy, sex, or disease-risk assessment. The recommendations presented in this review will aid the safe administration of lenalidomide for the treatment of patients with low-risk or intermediate-1-risk MDS and a del(5q) cytogenetic abnormality, and they will help physicians avoid unnecessary dose reduction or interruption, thus assuring the best efficacy for patients.

KW - Lenalidomide

KW - MDS

KW - Myelodysplastic syndromes

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=41549102420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549102420&partnerID=8YFLogxK

U2 - 10.1007/s00277-008-0449-0

DO - 10.1007/s00277-008-0449-0

M3 - Article

VL - 87

SP - 345

EP - 352

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -